EU Regulators Up The Number of Tysabri-Related PML Cases, Re-Open a Safety Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen, Elan shares take a dive as the EMEA says it's found ten previously undisclosed cases of the deadly brain infection.
You may also be interested in...
Tysabri Webcast Citation May Signal That FDA Could Treat All Social Media Interactions As Promotional; Biogen's PML Strategy Also Takes A Hit
FDA appears to be gearing up to treat social media interactions as promotional even when they are aimed solely at informing physicians
Tysabri Webcast Citation May Signal That FDA Could Treat All Social Media Interactions As Promotional; Biogen's PML Strategy Also Takes A Hit
FDA appears to be gearing up to treat social media interactions as promotional even when they are aimed solely at informing physicians
Tysabri Risk Communication Goes Beyond REMS With Monthly Update For Docs
Biogen Idec's decision to start providing doctors with monthly updates on progressive multifocal leukoencephalopathy cases among Tysabri patients shows the firm's confidence that providing additional risk information will not discourage use of the product